AnimalBiome Company Profile

Background

Overview

Founded in 2016, AnimalBiome is a biotechnology company headquartered in Oakland, California, specializing in pet gut health. The company offers microbiome-based supplements and non-invasive diagnostics to address chronic digestive disorders in dogs and cats. AnimalBiome's mission is to revolutionize animal health by leveraging microbiome science to create products that enhance the quality of life for companion animals. The company is recognized for its significant contributions to the pet health industry, particularly in understanding and supporting the gut microbiome.

Mission and Vision

AnimalBiome's mission is to improve pet health by utilizing microbiome science to develop products that enhance the quality of life for companion animals. The company's vision is to ensure that pets, as full members of families, live to their full potential through a deep understanding of the essential roles that the microbiome plays in animal health.

Industry Significance

AnimalBiome holds a significant position in the pet health industry, particularly in the emerging field of microbiome research. By focusing on the gut microbiome, the company addresses a critical aspect of animal health, offering innovative solutions for chronic digestive and skin conditions in pets. Its work has contributed to a broader understanding of how microbiome imbalances affect companion animals and has paved the way for new treatment approaches.

Key Strategic Focus

Core Objectives

AnimalBiome aims to advance pet health through gut and oral microbiome research and products, creating a new category within the growing pet food, supplement, and veterinary care market. The company's objectives include developing microbiome-based supplements, providing non-invasive diagnostics, and conducting research to better understand the role of the microbiome in pet health.

Areas of Specialization

The company specializes in microbiome assessment, microbial biomarkers for chronic health conditions, fecal transplant pills for pets, personalized medicine for pets, and solutions for cat and dog health, including digestive, skin, and oral health.

Key Technologies Utilized

AnimalBiome employs next-generation sequencing and powerful analytics software to identify and analyze over 5,000 types of bacteria in pet fecal samples. This technology enables the company to provide comprehensive microbiome assessments and develop targeted supplements to restore gut health.

Primary Markets Targeted

The primary markets targeted by AnimalBiome include pet owners seeking to improve their pets' gut health and veterinarians looking for advanced diagnostic tools and treatments for chronic digestive and skin conditions in companion animals.

Financials and Funding

Funding History

AnimalBiome has raised a total of approximately $29.87 million in funding over several rounds. The most recent funding round was a Series A investment of $8.6 million, closed in July 2021. This round was led by Cargill, with additional investors including SOSV (IndieBio), Moai Capital, Digitalis Ventures, Michelson Found Animal Foundation, and R/GA Ventures.

Utilization of Capital

The capital raised is intended to accelerate growth and create new microbial cocktails for companion animals. The funding supports the development of microbiome-based supplements and diagnostics, as well as research initiatives to better understand and address chronic digestive and skin conditions in pets.

Pipeline Development

Key Pipeline Candidates

AnimalBiome is developing microbiome-based supplements and diagnostics aimed at restoring gut health in pets. These products are designed to address chronic digestive and skin conditions by reintroducing beneficial bacteria and balancing the gut microbiome.

Stages of Development

The company's products are in various stages of development, including research, clinical trials, and market introduction. AnimalBiome has conducted studies to characterize the microbiome of cats on different diets and is actively involved in research to identify key beneficial gut microbes.

Target Conditions

The primary conditions targeted by AnimalBiome's products include chronic digestive disorders and skin conditions in dogs and cats, such as diarrhea, vomiting, and itchy skin.

Anticipated Milestones

AnimalBiome anticipates milestones related to the development and commercialization of its microbiome-based supplements and diagnostics, aiming to provide effective solutions for chronic digestive and skin conditions in pets.

Technological Platform and Innovation

Proprietary Technologies

AnimalBiome utilizes next-generation sequencing technology to analyze the full-length 16S rRNA gene in pet fecal samples, enabling precise identification of over 5,000 types of bacteria. This approach allows for comprehensive microbiome assessments and the development of targeted supplements.

Significant Scientific Methods

The company employs advanced sequencing techniques and sophisticated software to analyze microbiome data, providing detailed insights into the gut microbiome composition of pets. This scientific methodology supports the development of personalized action plans for improving pet gut health.

Leadership Team

Key Executives

• Carlton Osborne: Chief Executive Officer and Co-Founder. Osborne has a background in business development and has been instrumental in leading AnimalBiome's growth and strategic direction.

• Holly Ganz: Chief Science Officer and Co-Founder. Ganz is a microbiome scientist with expertise in animal health, leading the company's scientific research and product development efforts.

Leadership Changes

In July 2021, Carlton Osborne was appointed as the Chief Executive Officer.